Recent advances in proton pump inhibitors

IDrugs

Volumn 3, Issue 9, 2000, Pages 1064-1074

  Tam, Tim ^a   Li, Wanren ^a   Leung Toung, Regis ^a   Karimian, Khashayar ^a  

^a Apotex Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0009088679     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Ulcer fact sheet: Peptic ulcer disease. American Digestive Health Foundation. http://www.gastro.org/adhf/ulcers.html
2. Engel Publishing Partners: The top 500 prescription drugs by the therapeutic category: Gastrointestinal products. Med Ad News (1999) 18(5):23.
3. Schwartz K: Ueber penetrierende Magen- und Jejunal Gechuere. Beitr Klin Chirurgie (1910) 5:98.
4. Antiulcer drugs. The Year New Drugs (1994) 229-240.
5. SG Cowen Securities Corporation: Pharmaceutical Therapeutic Categories Outlook: Part 21. Analyst Report. (1999) SG Cowen Securities Corporation.
6. + ATPase. Annu Rev Pharmacol Toxicol (1995) 35:277-305.
7. 2-type ATPases. J Biol Chem (1999) 274(20):13737-40.
8. Sachs G: Proton pump inhibitors and acid-related diseases. Pharmacotherapy (1997) 17:22-37.
9. Brandstrom A, Lindberg P, Bergman N-A, Alminger, T, Anker, K, Junggem U, Lamm B, Nordberg P, Erickson M, Grundevik I, Hagin I, Hofmann J, Johansson S, Larsson S, Lofberg I, Ohlson K, Persson B, Skanberg I, Tekenbergs-Hijelte T: Chemical reactions of omeprazole and omeprazole Analogues. I. Survey of the chemical transformations of omeprazole and its analogues. Acta Chem Scand (1989) 43:536-548.
10. Lindberg P, Brandstorm A, Wallmark B, Mattsson H, Rikner L, Hoffman K-J: Omeprazole: The first proton pump inhibitor: Med Res Rev (1990) 10:1-53.
11. Huber R, Kohl B, Sachs, G, Senn-Bilfinger, J, Simon WA, Strum E: The continuing development of proton pump inhibitors. Aliment Pharmacol Ther (1995) 9:363-378.
12. Scherrer RA, Howard SM: Use of distribution coefficients in quantitative structure-activity relationships. J Med Chem (1997) 20:53-58.
13. Segal BG: Chemistry experiments and theory. John Wiley and Sons, New York (1985) 275.
14. Lindberg P, Nordberg P, Alminger, T, Brandstrom A, Wallmark B: The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem (1986) 29:1327-9.
15. Tucker GT: The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther (1994) 8(Suppl 1):33-38.
16. Feret B, Quercia RA, Cappa J: Rabeprazole: A proton pump inhibitor for the treatment of acid-related disorders. Formulary (1999) 34:313-323.
17. Huber R, Kohl B, Sachs, G, Senn-Bilfinger, J, Simon WA, Strum E: The continuing development of proton pump inhibitors. Aliment Pharmacol Ther (1995) 9:363-378.
18. Kromer W, Horbach S, Luhmann R: Relative efficacies of gastric proton pump inhibitors. Their clinical and pharmacological basis. Pharmocology (1999) 59:57-77.
19. Blum R A: Lasoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health-Syst Pharm (1996) 53:1401-1415.
20. Kromer W: Similarities and differences in the properties of substituted benzimidazole: a comparison between pantoprazole and related compounds. Digestion (1995) 56:443-454.
21. Sachs G, Humphries TJ: Rabeprazole: pharmacology, pharmacokinetics, and potential for drug interaction. Introduction. Aliment Pharmocol Ther (1999) 13 (Suppl 3):1-2.
22. Hatlebakk, JG, Berstad A: Pharmacokinetic optimization in the treatment of gastroesoesophagel reflux disease. Clin Pharmacokin (1996) 31:386-406.
23. +-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors. J Med Chem (1991) 34:1049-1062.
24. Anderson T: Pharmacokinetics, metabolism and interaction of acid inhibitors. Clin Pharmacokin (1996) 31:9-28.
25. Ishizaki T, Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther (1999) 13:27-36.
26. Meyer UA: Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions. Yale J Biol Med (1996) 69:203-209.
27. Savarino V, Mela GS, Zentilin P, Cutela P, Mele MR, Vigneri S, Celle G: Variability in individual response to various doses of omeprazole. Digest Dis Sci (1994) 39:161-168.
28. Regardh CG, Langerstrom PO, Lundborg P, Skanberg I: The pharmacokinetics of omeprazole in humans - A study of single intravenous and oral doses. Ther Drug Monit (1990) 12:163-171.
29. Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizka T: Disposition kinetics of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther (1992) 262:1195-1202.
30. Pope AJ, Parsons ME: Reversible inibitors of the gastric H+/K+-transporting ATPase: a new class of anti-secretory agent. Trends Pharmacol Sci (1993) 14:323-325.
31. Humphries TJ, Merritt GJ: Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther (1999) 13:18-26.
32. Unge P, Anderson T: Drug interactions with proton pump Inhibitors. Drug Saf (1997) 16:171-179.
33. Steinijas, VW, Huber R, Hartmann M; Zech K; Bliessath H; Wurst W, Radtke HW: Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther (1996) 34:531-550.
34. Wingate DL: Acid reduction and recurrent enteritis. Lancet (1990) 335(8683):222.
35. Lamer AJ, Lendrum R: Oesophageal acid clearance. Gut (1992) 33:860-861.
36. + inhibitors on Helicobacter pylori infection. Pharmacol Ther (1996) 69:79-83.
37. Hatlebakk, JG, Berstad A: Pharmacokinetic optimization in the treatment of gastroesoesophagel reflux disease. Clin Pharmacokinet (1996) 31:386-406.
38. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G: Pharmacology and toxicology of omeprazole - with special reference to the effect on gastric mucosa. Scand J Gastroenterol (1986) 21:31-38.
39. Berlin RG: Omeprazole: gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci (1991) 36:129-136.
40. Long JF, Chiu p JS, Derelanko MJ, and Steinberg M: Gastric antisecretory cytoprotective activities of SCH 28080. J Pharmacol Exp Ther (1983) 226:114-120.
41. Kaminski JJ, Perkins DG, Frantz JD, Solomon DM, Elliot AJ, Chiu PJS, Long JF: Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted [1,2-a]pyridines and a related imidazo[1,2-a]pyrazine. J Med Chem (1987) 30:2047-2051.
42. Wurst W, Hartmann M: Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med (1997) 69:233-243.
43. Martinek J, Blum AL, Stolte M, Hartmann M, Verdu EF, Luhmann R, Dorta G, Wiesel P: Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther (1999) 13:27-34.
44. Kim KB, Chang MS, Chung YK, Sohn SK, Kim SG, Choi WS: Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats. J Pharm Pharmacol (1998) 50:521-529.
45. Sohn S-K, Chang M-S, Chung Y-K, Kim K-B, Woo T-W, Lee S-B, Choi W-S: The single dose toxictty of 3-butyryl-4-[5-(R)-(+)-methylbenzylamino]8-ethoxy-1,7-naphthyiridine (YJA20379-8) in rats. Pharmacometrics (1998) 56:63-66.
46. Hersey S J, Sachs G: Gastric acid secretion. Physiol Rev (1995) 75:155-189.
47. + ATPase. Annu Rev Pharmocol Toxicol (1995) 35:277-305.
48. Ife RH, Brown TH, Blurton P, Keeling DJ, Leach CA, Meeson ML, Parsons ME, Theobald CJ: Reversible inhibitors of gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines. J Med Chem (1995) 38:2763-2773.
49. +-ATPase. J Med Chem (1990) 33:543-552.
50. +-ATPase inhibitors. Bioorg Med Chem Lett (1997) 7:527-532.
51. Kaminski J, Doweyko AM: Antiulcer agents: 6. Analysis if the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies. J Med Chem (1997) 40:427-436.
52. +-ATPase. Bioorg Med Chem Lett (1995) 5:543-546.
53. +)-ATPase. Biochem Phamacol (1991) 42:123-130.
54. von Unge S, Langer V, Sjolin L: Stereochemical assignment of enantiomers of omeprazole from X-ray analysis of fenchyloxymethyl derivartive of (+)-(R)-omeprazole. Tetrahedron Asymmetry (1997) 12:1967-1970.
55. Archibald K: Seventh Congress on Clinical Pharmacology and Therapeutics: Gastrointestinal pharmacology IDdb Meeting Report (2000) July 15-20.
56. Kinoshita M, Satio N, Takami H: Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats. Eur J Pharmacol (1997) 321:325-332.
57. +ATPase. J Med Chem (1988) 31:1215-1220.
58. +-ATPase by T-330, 2-[(2-dimethylamino benzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole. J Pharmacol Exp Ther (1996) 277:28-33.
59. +-ATPase inhibitors. Chem Pharm Bull (1991) 39:1746-1752.
60. +-ATPase inhibitors. J Med Chem (1996) 39: 596-604.
61. Yamada S-I, Yamaguchi T, Aihara K, Nagai A, Kogi K, Narita S-I: Biological activities of four stereoisomers of 2-(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylsulfinyl)1H- benzimidazole sodium salt and acid-induced transformation: Novel proton pump inhibitor. Chem Pharm Bull (1996) 44:215-221.
62. Fava A, Iliceto A, Camera E: Kinetics of thiol disulfide exchange. J Am Chem Soc (1957) 79:833-838.
63. The synthesis and reactions of organic compounds. In: Comprehensive Organic Chemistry. D Neville Jones (Ed), Pergamon Press 290-291.
64. Zahradnik R, Koutecky J: Contribution to the chemistry of thiadiazole and 1,3-thiazole. Coll Czech Chem Comm (1961) 26:156.
65. +-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl-and benzsulfinyl)nicotinamides. J Med Chem (1997) 40:313-321.
66. Chung YK, Chang MS, Kim KB, Sohn SK, Woo TW, Lee SB, Choi WS: The biochemical and pharmacological properties of a newly synthesized H+-K+ ATPase inhibitor, 2-dimethylamino-4,5-dihydrothiazolo[4,5:3,4]pyridol-[1,2-a] benzimidazole. Can J Physiol Pharmacol (1998) 76:921-929.
67. Sohn SK, Chang MS, Chung YK, Kim KB, Woo TW, Kim SG, Choi WS: Biochemical and pharmacological properties of a new proton pump inhibitor, 2-amino-4,5-dihydropyrido[1,2-a]thiazolo[5,4-g]benzimidazole (YJA20379-5). Arch Pharm Res (1998) 21:241-247.
68. Woo TW, Chang MS, Chung YK, Kim KB, Sohn SK, Kim SG, Choi WS: Inhibitory action of YJA20379, a new proton pump inhibitor on Helicobacter pylori growth and urease. Arch Pharm Res (1998) 21:6-11.
69. Metzger JV: Thiadiazoles and their benzo derivatives. In: Comprehensive Heterocyclic Chemistry. Katritsky AR, Rees CW (Eds), Pergamon Press (1984).
70. Woo TW, Chang MS, Chung YK, Kim KB, Sohn SK, Kim SG, Choi WS: Effects of YJA20370-4 on gastric secretion, Helicobacter pylori growth and various gastric and duodenal lesions in rats. Biol Pharm Bull (1998) 21:449-455.
71. Sewing KF, Beil W, Hanneman H, Klemm K, Senn-Bilfinger J: The biologically active form of substituted benzimidazoles. Hepato-gastroentrology (1984) 5:523.
72. Fryklund J, Wallmark B: Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms. J Pharmacol Exp Ther (1986) 236:248-253.
73. APOTEX INC (Lee JW, Chae JS, Kim CS, Kim JK, Lim DS, Shon M, Choi YS, Lee SH): Pyrimidine derivatives and processes for the preparation thereof. US-05750531 (1998).
74. APOTEX INC (Kim SU, Kim DY, Chung G, Hong SK, Park SJ, Nam SH, Lee YS): 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives. US-05703097 (1997).
75. APOTEX INC (Karimian K, Tam TF, Desilets D, Lee S, Cappelletto T, Li W): Thiadiazole compounds useful as proton pump inhibitors. US-05677302 (1997).
76. APOTEX INC (Karimian K, Tam TF, Desilets D, Lee S, Cappelletto T, Li W): Process for scavenging thiols. EP-00883606 (1998).